GEMIN5: A Potential Drug Target and Biomarker (G25929)

Target Name: GEMIN5

NCBI ID: G25929

GEMIN5

GEMIN5: A Potential Drug Target and Biomarker

Gemin5, a gene named after the word \"gemini,\" is a unique human gene that has been identified by researchers as having the potential to serve as a drug target and biomarker. Gemin5 is located on chromosome 16 and is responsible for the production of a protein known as GEMIN5, which is involved in a variety of cellular processes.

Gemin5 and its associated protein have been shown to play a key role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, the GEMIN5 protein has also been shown to have potential as a drug target, with researchers suggesting that it may be able to interact with and modulate the activity of other proteins involved in disease progression.

One of the key features of the GEMIN5 protein is its ability to interact with the protein known as TOR, which is a key regulator of cell growth and metabolism. TOR is a protein that is involved in the production of protein substrates, including the protein S6, which is known to play a role in the development of cancer.

Research has shown that the GEMIN5 protein is able to interact with TOR and inhibit its activity, which could have implications for the regulation of cell growth and metabolism. This may be important for the development of cancer, as altered levels of cell growth and metabolism can contribute to the development of cancer.

Another potential drug target for GEMIN5 is its role in the regulation of the immune system. GEMIN5 has been shown to be involved in the development and function of natural killer cells, which are a critical part of the immune system. Research has suggested that GEMIN5 may play a key role in the regulation of natural killer cell development and function, and that alterations in GEMIN5 activity may contribute to the development of immune disorders such as cancer.

In addition to its potential as a drug target, GEMIN5 has also been shown to be a potential biomarker for a variety of diseases. For example, GEMIN5 has been shown to be involved in the regulation of cell death, which could be an important biomarker for neurodegenerative diseases such as Alzheimer's and Parkinson's.

GEMIN5 has also been shown to be involved in the regulation of inflammation, which could be an important biomarker for autoimmune disorders such as rheumatoid arthritis and multiple sclerosis. In addition, GEMIN5 has been shown to be involved in the regulation of stem cell proliferation, which could be an important biomarker for the development and treatment of stem cell-based therapies.

Overall, GEMIN5 is a unique and promising gene that has the potential to serve as a drug target and biomarker. Its involvement in the regulation of cell growth and metabolism, as well as its potential as a drug target and biomarker, makes it an important area of research for scientists and clinicians alike. Further studies are needed to fully understand the role of GEMIN5 in disease progression and the development of new treatments.

Protein Name: Gem Nuclear Organelle Associated Protein 5

Functions: The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:16857593, PubMed:18984161, PubMed:20513430, PubMed:33963192). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core). In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP (PubMed:18984161). To assemble core snRNPs, the SMN complex accepts the trapped 5Sm proteins from CLNS1A forming an intermediate (PubMed:18984161). Binding of snRNA inside 5Sm ultimately triggers eviction of the SMN complex, thereby allowing binding of SNRPD3 and SNRPB to complete assembly of the core snRNP. Within the SMN complex, GEMIN5 recognizes and delivers the small nuclear RNAs (snRNAs) to the SMN complex (PubMed:11714716, PubMed:16857593, PubMed:19377484, PubMed:19750007, PubMed:20513430, PubMed:27834343, PubMed:27881600, PubMed:27881601, PubMed:16314521). Binds to the 7-methylguanosine cap of RNA molecules (PubMed:19750007, PubMed:27834343, PubMed:27881600, PubMed:27881601, Ref.27). Binds to the 3'-UTR of SMN1 mRNA and regulates its translation; does not affect mRNA stability (PubMed:25911097). May play a role in the regulation of protein synthesis via its interaction with ribosomes (PubMed:27507887)

The "GEMIN5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GEMIN5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets